Announcements Trials
Browse Landscape

Phase

Phase 2 39Phase 3 17Phase 1/2 4Phase NA 2

Status

Completed 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Amyloidosis 1

Interventions

Cyclophosphamide 143pembrolizumab 127Nivolumab 116Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 73Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Ipilimumab 55Docetaxel 54Bortezomib 54Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × Thalidomide × Clear all
NCT02545907 2021-04-15

CATALYST

University College, London

Phase 1/2 Completed
10 enrolled 14 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT00966693 2020-11-04

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

M.D. Anderson Cancer Center

Phase 1/2 Completed
77 enrolled 19 charts
Plasma cell

Multiple Myeloma

NCT01057225 2017-12-12

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
64 enrolled 13 charts
Plasma cell

Multiple Myeloma

NCT00096018 2013-10-24

Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Roswell Park Cancer Institute

Phase 1/2 Completed
43 enrolled 8 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡